PASG - יחס חוב להיוון בספרים passagebio.com

Passage Bio, Inc. (PASG) develops gene therapies to combat severe brain pathologies, demonstrating complete independence from economic cycles. The distribution of debt within the balance sheet capitalization shows that the indicator value reaches 0.00, while the expert team effectively manages clinical trials. Future scaling potential relies on the high value of innovative medicines, despite the current increase in operating expenses.

The development of gene therapies at Passage Bio, Inc. (PASG) involves high capital burn prior to product commercialization. This ratio correlates total liabilities with equity, determining the business's degree of dependence on borrowed funds. The metric allows for an assessment of financial autonomy and the balance sheet structure's resilience to external shocks. An increase in this value signals critical leverage. By analyzing the company's total debt-to-equity ratio, an investor identifies hidden bankruptcy risks.